A Study With Darapladib to Collect Tolerability Information

Summary

Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home. Subjects will record any adverse events throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days after the last dose of darapladib for a follow-up visit. The total study duration for each subject including the screening, treatment and follow-up periods will be approximately 4 weeks.

Timeline

Start

2008-05

Primary completion

2008-10

Completion

2008-10

Drugs

Indications